Mosaic ImmunoEngineering Inc. is a development-stage biotechnology company. It is focused on bridging immunology and engineering to develop novel immunotherapies to treat and prevent cancer and infectious diseases. The company's product pipeline includes MI-O-101. Mosaic ImmunoEngineering Inc., formerly known as Patriot Scientific Corporation, is based in NOVATO, CA.
| Revenue (Most Recent Fiscal Year) | -- |
| Net Income (Most Recent Fiscal Year) | $-0.92M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | -- |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | -- |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -- |
| Net Margin (Trailing 12 Months) | -- |
| Return on Equity (Trailing 12 Months) | -- |
| Return on Assets (Trailing 12 Months) | -1117.89% |
| Current Ratio (Most Recent Fiscal Quarter) | 0.02 |
| Quick Ratio (Most Recent Fiscal Quarter) | 0.02 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | -- |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $-0.96 |
| Earnings per Share (Most Recent Fiscal Quarter) | -- |
| Earnings per Share (Most Recent Fiscal Year) | -- |
| Diluted Earnings per Share (Trailing 12 Months) | $-0.12 |
| Exchange | -- |
| Sector | -- |
| Industry | -- |
| Common Shares Outstanding | 7.24M |
| Free Float | 1.38M |
| Market Capitalization | $1.97M |
| Average Volume (Last 20 Days) | 788.20 |
| Beta (Past 60 Months) | 0.11 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 80.99% |
| Percentage Held By Institutions (Latest 13F Reports) | 0.00% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |